Morgan Lewis

Related Publications

11/22/10 Keep One Eye on the Collaboration, And the Other on Exit Events, New Jersey Law Journal (read the article)
November 2002 Changing Environment for Pharma-Biotech Collaborations, New Jersey LifeSciTech , Q4
View all publications

Related News

10/03/13 Morgan Lewis Receives 2013 LMG Life Sciences Awards
Morgan Lewis was named Healthcare Pricing and Reimbursement Firm of the Year at the inaugural LMG Life Sciences awards ceremony.
09/24/09 Morgan Lewis Advises LEO Pharma on $1 Billion Acquisition
Morgan Lewis represented LEO Pharma in the $1 billion acquisition of exclusive product licensing rights and inventories from LEO Pharma by Warner Chilcott plc.
View all news

Emerging Business Tools

visit the Entrepreneur Resource Headquarters
Photo of  David G. Glazer

honors + affiliations

Certified Licensing Professional

Listed, Chambers USA: America's Leading Lawyers for Business (2008–2009, 2013-2014)

Listed, Legal Media Group's Life Sciences "Life Sciences Star" – Transactional (2012–2013)

Member, New Jersey Bar Association

Articles Editor, New York University Environmental Law Journal

bar admissions

  • New Jersey
  • Pennsylvania
print profile

David G. Glazer

502 Carnegie Center
Princeton, NJ 08540-6289
United States of America
Phone: +1.609.919.6624
Fax: +1.609.919.6701

David G. Glazer is a partner in Morgan Lewis's Business and Finance Practice and co-editor of the Morgan Lewis Deskbook for Emerging Growth Life Sciences Companies. Mr. Glazer's practice focuses on advising and representing technology companies, primarily in the life sciences and information technology industries. His clients range from early-stage biotechnology startups to global fortune 100 pharmaceutical companies, including medical device and specialty pharmaceutical companies. Mr. Glazer regularly serves as outside counsel to these companies and counsels them in a variety of different transactions as well as strategic advice. His practice includes negotiation and structuring of licensing and other complex collaborations, corporate partnering arrangements, strategic alliances, mergers and acquisitions, supply and distribution arrangements, co-promotions and joint ventures, ranging from early-stage research collaborations to global alliances to develop and commercialize products. In addition, Mr. Glazer advises and counsels private equity, venture capital, and investment banking firms that focus on the life sciences industry.

Mr. Glazer is the author or co-author of a number of articles relating to the life sciences industry including: "Keep One Eye on the Collaboration, And the Other on Exit Events," New Jersey Law Journal, November 22, 2010; "Dividing the Intellectual Property Pie in the Life Sciences Industry," New Jersey Law Journal, April 14, 2011; and, "Changing the Environment for Pharma-Biotech Collaborations, New Jersey LifeSciTech, Q4.

Mr. Glazer is admitted to practice in New Jersey and Pennsylvania and is a Certified Licensing Professional.

Selected Representations

  • Lumiphore in its agreement with Algeta for worldwide license to Lumiphore’s patented chelator technology to be used for cancer therapeutics
  • BTG in its acquisition of the U.S. commercial rights to Wellstat Therapeutics Corporation's product candidate uridine triacetate
  • Merck in its joint venture with Sun Pharmaceutical Industries for innovative formulations
  • Lundbeck in its commercial rights agreement with Cephalon to register and commercialize several Cephalon products including Fentora, Provigil, Treanada, Trisenox, Myocet and Nuvigil in Canada and Latin America
  • BTG in the $180 million acquisition of EKOS Corporation
  • MEI Pharma in its acquisition from S*BIO of the rights to Pracinostat, a clinical stage oncology drug
  • LifeNet Health in its acquisition of Northwest Tissue Services from Puget Sound Blood Center
  • Axcan Pharma in its sale of the pharmaceutical products, Photofrin and Photobarr, to Pinnacle Biologics
  • Acura Pharmaceuticals in its exclusive license, development and commercialization agreement for North America with King Pharmaceuticals for opioid analgesic products utilizing Acura's patented Aversion® (abuse deterrent) Technology platform
  • NPS Pharmaceuticals in the restructuring and sale of its mGluRs collaboration with AstraZeneca
  • Novo Nordisk in its agreement with Sciele Pharma for Sciele to market Prandin® and, upon approval by the US Food and Drug Administration, PrandiMet
  • Axcan Pharma in its exclusive license and development agreement with Cellerix SL of Spain, for the North American rights to Cellerix's biological product using non-embryonic stem-cells
  • Schering-Plough in its global collaboration with Novartis to develop and commercialize a once-daily inhaled fixed-dose combination therapy for asthma and COPD
  • Pharmasset in its development and commercialization collaboration with Bukwang Pharmaceuticals of Korea for the treatment of chronic hepatitis B virus
  • Enzon in its LNA oncology development and commercialization alliance with Santaris
  • Shire in its up to $500 million collaboration with New River Pharmaceuticals for the development and commercialization of a late-stage ADHD compound
  • Schering-Plough in its acquisition of Bayer AG's primary care pharmaceutical product business in the United States and related strategic alliances on oncology products and on Zetia® in Japan
  • Paul Royalty Fund in its revenue monetization agreement with Glenmark Pharmaceuticals
  • Adolor in its co-promotion agreement with GlaxoSmithKline for Arixtra®
  • Sanofi-Aventis in the divestiture of Campto® to Pfizer
  • Adolor in its worldwide development and commercialization collaboration for Entereg® with GlaxoSmithKline
  • Sanofi-Aventis in its up to $485 million collaboration with Regeneron to develop and commercialize VEGF-Trap products, and related equity investment
  • NexMed in its licensing, development and commercialization collaboration with Novartis for its fungal product
  • Sanofi-Aventis in the outsourcing of certain clinical and regulatory functions to Quintiles
  • Adolor in its late-stage licensing transaction with EpiCept for the development and commercialization of LidoPain® SP and related products
  • Aventis in its up to $480 million collaboration with Genta for the co-development and co-commercialization of Genasense®, an antisense oncology compound, and related equity investment
  • Aventis in its $450 million alliance with Millennium Pharmaceuticals for target-based drug discovery and commercialization, bioinformatics technology transfer and related equity investment
  • 3-Dimensional Pharmaceuticals in drug discovery alliance with Bristol-Myers Squibb
  • Enzon in its acquisition of Abelcet® product rights and related manufacturing facility and other assets from Elan for $370 million


  • New York University School of Law, 1997, J.D.
  • Rutgers University, 1994, B.A.